Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Eli Lilly released a new form of its weight loss ... The company and its rival Novo Nordisk have both stepped in to address ...

Lilly has announced a significant expansion of its manufacturing presence in Ireland, with a $1bn investment earmarked for ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

which helps to identify and address challenging drug targets that are difficult to treat with conventional methods. Eli Lilly announced positive results from two phase 3 clinical trials (QWINT-1 ...

Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Eli Lilly and Company has revealed positive topline results from the Phase III trials of efsitora alfa to treat adults with ...

Eli Lilly (NYSE: LLY) offers investors the same ... By launching a split, Lilly could immediately address this problem, making it easier for a broader range of investors to buy shares.